Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of radiotherapy plus Erbitux with or without concurrent carboplatin/5-fluorouracil in locally advanced head and neck squamous cell carcinoma
2007-002004-18Phase 3Completed
- Sponsor
- GORTEC
- Start
- Sep 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab, carboplatin, fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Sep 2007; status: completed.
02
Drugs
cetuximabcarboplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-002004-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002004-18.